Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of curcumin in non-alcoholic fatty liver disease
IRCT201702209662N12Phase 2Completed
- Sponsor
- Isfahan Cardiovascular Research Center
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of curcumin in metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatitis, sponsored by Isfahan Cardiovascular Research Center. Started Oct 2016; status: completed.
02
Drugs
curcumin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatitis
Beyond the preview
Go deeper on IRCT201702209662N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201702209662N12.